BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

TAOYUAN, Taiwan (Reuters) -The first batch of BioNTech SE's COVID-19 vaccine arrived in Taiwan on Thursday, helped by the involvement of two of the world's most important tech firms after months of heated political and diplomatic wrangling. Taiwan has blamed China, which claims the island as its own territory, for nixing an original order from the German firm this year - charges Beijing has angrily denied.

Helped by TSMC and Foxconn, BioNTech vaccines finally reach Taiwan

Abercrombie & Fitch

Dick's Sporting Goods

Kohl's

Pfizer

Rent-A-Center

We have narrowed down our search to five stocks that have provided more than 20% returns year to date. These are: DKS, KSS, ANF, RCII and HPQ.

5 Top Picks to Boost Portfolio in Historically Weak September

There appears to be a great wall in China keeping BioNTech's vaccine out.

Why BioNTech's COVID Vaccine Is Blocked From the World's Biggest Market

Moderna

A study comparing individual immune responses to two major COVID-19 vaccines has shown that Moderna's created more than double the antibodies than that of Pfizer and BioNTech.

Moderna's COVID-19 vaccine created more antibodies than Pfizer/BioNTech's in study of vaccinated Belgian health-care workers

The shares of BioNTech SE (NASDAQ: BNTX) have received a price target of $450 from Canaccord. These are the details.

BNTX Stock: $450 Price Target From Canaccord

China's government is reportedly slowing the approval for its first foreign COVID-19 vaccine because it could undermine confidence in Chinese vaccines. Health authorities are concerned that public doubts about Chinese vaccines stemming from the approval of Pfizer Inc (NYSE: PFE) - BioNTech SE's (NASDAQ: BNTX) vaccine could disrupt the country's plans to use the homegrown shots.

China Holds Up BioNTech's COVID-19 Jab Approval: WSJ

BioNTech SE (NASDAQ: BNTX) is looking into building malaria and tuberculosis vaccine production sites in Rwanda and Senegal. The Company said that future malaria and tuberculosis vaccines would be based on the so-called messenger RNA technology used in its COVID-19 shot.

BioNTech Evaluates Rwanda And Senegal For Malaria, Tuberculosis Vaccine Production

Friday's announcement comes as debate grows over the moral obligation of richer countries to share the Covid-19 vaccines with poorer ones.

BioNTech Plans to Make Its Malaria, TB Vaccines in Africa

The teams at Moderna, Pfizer and BioNTech recount the historic race to develop Covid-19 vaccines in a newly released documentary by CNBC.

A race against Covid: How Moderna and Pfizer-BioNTech developed vaccines in record time

BERLIN, GERMANY, August 27, 2021 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) agreed today to evaluate the establishment of sustainable vaccine manufacturing capabilities in Rwanda and Senegal to support vaccine supply for the Member States of the African Union. Following the invitation of the kENUP Foundation, President Paul Kagame of Rwanda, President Macky Sall of Senegal, and President Ursula von der Leyen of the European Commission met Uğur Şahin, CEO and Co-Founder of BioNTech in Berlin to discuss the development of sustainable vaccine production for Africa. The meeting resulted in a joint communiqué affirming BioNTech's intention to manufacture mRNA vaccines arising from its Malaria and Tuberculosis vaccine development programs on the African continent.

Joint Communiqué: BioNTech Evaluates mRNA Vaccine Manufacturing Solutions in Rwanda and Senegal to Improve Long-Term Vaccine Supply

The booster dose of Pfizer (PFE)/BioNTech's (BNTX) mRNA-based COVID-19 vaccine, Comirnaty dose induced significant SARS-CoV-2 neutralizing antibody titers in phase III study.

Pfizer (PFE), BioNTech Seek Full Approval for COVID Jab Booster

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have partnered with Eurofarma Laboratórios SA, a Brazilian biopharmaceutical company, to manufacture its COVID-19 vaccine for distribution within Latin America. Technical transfer, on-site development, and equipment installation activities will begin immediately.

Pfizer-BioNTech Ink COVID-19 Vaccine Manufacturing Pact For Latin America

Pfizer Inc. PFE, -1.80% and BioNTech SE BNTX, +2.13% said Thursday that they have signed a letter of intent (LOI) with Brazil-based biopharmaceutical company Eurofarma Laboratórios SA to make COVID-19 vaccines for distribution in Latin America. Eurofarma will receive drug product from the U.S., and will perform manufacturing activities, with distribution expected to start in 2022.

Pfizer, BioNTech sign LOI with Brazil's Eurofarma to make COVID-19 vaccines for use in Latin America

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a letter of intent with Eurofarma Laboratórios SA, a Brazilian biopharmaceutical company, to manufacture COMIRNATY® (COVID-19 Vaccine, mRNA) for distribution within Latin America. Eurofarma will perform manufacturing activities within Pfizer's and BioNTech's global COVID-19 vaccine supply chain and manufacturing network, which will now span four continents and includ

Pfizer and BioNTech Announce Collaboration With Brazil's Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America

Investor hype for this coronavirus biotech has reached an all-time high. Will it last?

Will BioNTech Be a Trillion-Dollar Company by 2023?

Maybe, but there were even more important considerations.

Did Pfizer's and BioNTech's FDA Submission Boost the Case for Booster Doses for All Americans?

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have initiated supplemental marketing application to the FDA seeking approval for its COVID-19 booster (third) shot. Earlier this week, Pfizer-BioNTech's COVID-19 Vaccine Became First To Receive Full FDA Approval.

Pfizer, BioNTech Now Seeking Full Approval For Third COVID-19 Vaccine Dose

BioNTech SE BNTX, +0.35% and Pfizer Inc. PFE, -2.03% said Wednesday that they initiated an application to U.S. regulators for a third dose of Comirnaty, their COVID-19 vaccine. BioNTech's stock was down 0.2% in trading on Wednesday, while Pfizer's stock fell 1.8%.

BioNTech, Pfizer initiate application for approval of a third dose of their COVID-19 vaccine

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for the approval of a booster (third) dose of COMIRNATY® (COVID-19 Vaccine, mRNA) to prevent COVID-19 in individuals 16 years of age and older. The companies intend to complete submission of the sBLA by the end of this week. The sBLA includes data from a Phase 3 clin

Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY® in Individuals 16 and Older

ProShares Ultra Nasdaq Biotechnology

The FDA has officially given full approval to Pfizer and BioNTech for their COVID-19 vaccine, potentially making way for more approvals and more vaccine mandates, reports CNBC. It is a move that officials are hoping will encourage those who have been reluctant to receive a vaccine to get vaccinated.

Pfizer-BioNTech COVID-19 Vaccine Garners Full FDA Approval

Novavax

The euphoria over full FDA approval of the Pfizer-BioNTech vaccine appears to be waning.

Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Sinking Today

Pfizer (PFE)/BioNTech's (BNTX) mRNA-based COVID-19 vaccine, Comirnaty becomes the first vaccine to be granted full approval by the FDA.

Pfizer (PFE)/BioNTech Comirnaty Gets FDA's Full Approval

Blackstone Group

ConocoPhillips

EOG Resources

MetLife

We have narrowed down our search to five large-cap stocks (market capital >$30 billion) that have popped more than 30% year to date. These are: AIG, MET, BX, COP and EOG.

Top 5 High-Yielding Stock Market Gainers YTD With More Upside

Analysts seem to be concerned about the uncertainties about what's next with COVID-19.

Why Wall Street Thinks BioNTech Stock Could Sink 25%

According to data published by the Health Ministry of Israel, the third dose of Pfizer Inc (NYSE: PFE) - BioNTech SE's (NASDAQ: BNTX)'s COVID-19 vaccine has significantly improved protection from infection and serious illness in people aged 60 and older compared with those who received two shots. Full details of the study were not released.

News for BioNTech SE Stock (BNTX)